UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/558,846	11/30/2005	Tsuneo Yasuma	2007_0365	1184
513 7590 04/09/2009 WENDEROTH, LIND & PONACK, L.L.P. 1030 15th Street, N.W., Suite 400 East Washington, DC 20005-1503			EXAMINER	
			CHANDRAKUMAR, NIZAL S	
			ART UNIT	PAPER NUMBER
			1625	
			MAIL DATE	DELIVERY MODE
			04/09/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/558,846	YASUMA ET AL.			
Office Action Summary	Examiner	Art Unit			
	NIZAL S. CHANDRAKUMAR	1625			
The MAILING DATE of this communication appeariod for Reply	pears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	PATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on <u>02/0</u> This action is FINAL . 2b) ☑ This 3) ☐ Since this application is in condition for alloward closed in accordance with the practice under the process.	s action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ☐ Claim(s) 1,3-6,12-15 and 18 is/are pending in 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1,3-6,12-15 and 18 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/o	wn from consideration.				
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accompliant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E.	cepted or b) objected to by the lead rawing(s) be held in abeyance. See tion is required if the drawing(s) is objected to by the lead rawing(s) is objected to be seen to be see	e 37 CFR 1.85(a). lected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate			

Art Unit: 1625

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 02/02/2009 has been entered.

Claims 1, 3-6, 12-15 and 18 are pending.

Objection: Base claim 1 contains a proviso excluding some of compounds; these compounds are outside the scope of the instant formula. Claim 5 is redundant as A is benzene as defined for the base claim 1.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Art Unit: 1625

Claims 1, 3, 5, 6, 12-15 and 18 rejected under 35 U.S.C. 102(e) as being anticipated by Bratton et al. (US 7244763, page 53; Provisional application filing date 04/17/2003) as well as Auerbach et al. (US 6875780, Provisional application filing date 04/05/2002, 06/05/2002).

Bratton et al. and Auerbach et al. teach

$$_{\rm F3C}$$
 $_{\rm CH_2-O}$ $_{\rm CH_2-O}$ $_{\rm CH_2-CO_2H}$ $_{\rm CH_2-C_OEt}$

corresponding to the compounds of the instant claims, wherein ring A is unsubstituted (instant claims is drawn to A ring being optionally substituted), X is CH2, n of Xb is 1, Xa is spacer having main chain of 2 atoms, Ar is substituted phenyl.

As for claim 18, the following is noted: The preamble of the claim 18 relating to GPR40 receptor function, is not given patentable weight because the property is inherent to the compound. A preamble is generally not accorded any patentable weight where it merely recites the purpose of a process or the intended use of a structure, and where the body of the claim does not depend on the preamble for completeness but, instead, the process steps or structural limitations are able to stand alone. See In re Hirao, 535 F.2d 67, 190 USPQ 15 (CCPA 1976) and Kropa v. Robie, 187 F.2d 150, 152, 88 USPQ 478, 481 (CCPA 195.)

Application/Control Number: 10/558,846

Art Unit: 1625

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1, 3-6, 12-15 and 18 rejected under 35 U.S.C. 103(a) as being unpatentable over Bratton et al. (7244763 Provisional application filing date 04/17/2003) as well as Auerbach et al. (US 6875780, Provisional application filing date 04/05/2002, 06/05/2002).

Bratton et al. and Auerbach et al. teach compounds encompassed by the instant formula.

Bratton et al. and Auerbach et al. do not teach all the conceivable compounds of the instant formula. The difference is that the substituents on the core formula of the instant case and in the prior art compounds are different but the differing groups are commonly employed substituents in the art to modify and optimize biological properties of otherwise pharmaceutically

Art Unit: 1625

active ingredients. Obviousness based on similarity of structure and functions entails motivation to make the claimed compound in expectation that compounds of similar in structure will have similar properties; therefore, one of ordinary skill in the art would be motivated to make the claimed compounds in searching for new compounds.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIZAL S. CHANDRAKUMAR whose telephone number is (571)272-6202. The examiner can normally be reached on 8.30 AM - 4.30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on 571 0272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/558,846 Page 6

Art Unit: 1625

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Nizal S. Chandrakumar

/D. Margaret Seaman/

Primary Examiner, Art Unit 1625